What we know, what we don’t know, and what’s next.
Early morning on May 18, Moderna, a biotechnology company, revealed the preliminary findings for the much anticipated phase 1 trial of an mRNA COVID-19 vaccine. The information sent Moderna’s stock soaring by more than 20% and helped fuel a rally on Wall Street.
Read the full article here.
This content was originally published by Fast Company. Original publishers retain all rights. It appears here for a limited time before automated archiving. By Fast Company